<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0300-9041</journal-id>
<journal-title><![CDATA[Ginecología y obstetricia de México]]></journal-title>
<abbrev-journal-title><![CDATA[Ginecol. obstet. Méx.]]></abbrev-journal-title>
<issn>0300-9041</issn>
<publisher>
<publisher-name><![CDATA[Federación Mexicana de Colegios de Obstetricia y Ginecología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0300-90412023000500344</article-id>
<article-id pub-id-type="doi">10.24245/gom.v88i8.4093</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Virus en el tratamiento de cáncer de mama]]></article-title>
<article-title xml:lang="en"><![CDATA[Viruses in the treatment of breast cancer.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Mariño]]></surname>
<given-names><![CDATA[Mario Arturo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Colombia  ]]></institution>
<addr-line><![CDATA[ Bogotá]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<volume>91</volume>
<numero>5</numero>
<fpage>344</fpage>
<lpage>365</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0300-90412023000500344&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0300-90412023000500344&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0300-90412023000500344&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  OBJETIVO: Sintetizar las conclusiones de artículos que estudiaron la aplicación de virus en el tratamiento de cáncer de mama humano.  METODOLOGÍA: Búsqueda bibliográfica de artículos registrados en PubMed, sin uso de filtros, efectuada en el mes de noviembre de 2019 con los términos: oncolytic virus in breast cancer. Los artículos seleccionados se agruparon en cuadros según el tipo de virus. Se obtuvieron datos del primer autor, año de publicación, vector y conclusiones principales.  RESULTADOS: Se encontraron 271 publicaciones de las que se excluyeron 128 en el cribado por título y resumen, 31 por tratarse de artículos de revisión. Si bien no hubo restricción por idioma, se excluyó un artículo en chino y seis cuyo objetivo principal fue el estudio del cáncer de mama en caninos. Las demás exclusiones se hicieron por falta de vínculo con el tema objeto de revisión. De los 143 artículos seleccionados para lectura completa se excluyeron 17 por no ser pertinentes con el objetivo, lo mismo que una comunicación breve.  CONCLUSIONES: La información seleccionada de virus para tratamiento de pacientes con cáncer de mama proviene casi toda de investigación preclínica con respuestas que favorecen la acción experimental de los oncovirus. En los estudios de investigación clínica, los resultados aún son escasos, pero insinúan su potencial de desarrollo, sobre todo en combinación con oncovirus o con otros agentes terapéuticos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  OBJECTIVE: To synthesise the findings of articles that studied the application of viruses in the treatment of human breast cancer.  METHODOLOGY: Bibliographic search of articles registered in PubMed, without the use of filters, carried out in November 2019 with the terms: oncolytic virus in breast cancer. The selected articles were grouped in tables according to the type of virus. Data were obtained on the first author, year of publication, vector and main conclusions.  RESULTS: With the search terms, 271 publications were found. Of these, 128 were excluded in the screening by title and abstract, 31 of them because they were review articles. Although there was no language restriction, one article in Chinese and six whose main objective was the study of canine breast cancer were excluded. The other exclusions were made because they were not associated with the subject under review. Among the 143 articles that were selected for full reading, 17 of them were also excluded as not relevant for the purpose of this review and one because it was a short communication.  CONCLUSIONS: The selected data on viruses for the treatment of breast cancer patients comes almost entirely from preclinical research with responses favoring the experimental action of oncoviruses. In clinical research studies, results are still scarce, but hint at their potential for development, especially in combination with oncoviruses or other therapeutic agents.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cáncer de mama]]></kwd>
<kwd lng="es"><![CDATA[virus]]></kwd>
<kwd lng="es"><![CDATA[tratamiento]]></kwd>
<kwd lng="en"><![CDATA[Breast cancer]]></kwd>
<kwd lng="en"><![CDATA[Virus]]></kwd>
<kwd lng="en"><![CDATA[Treatment]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wild]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Weiderpass]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
</person-group>
<source><![CDATA[World Cancer Report: Cancer Research for Cancer Prevention]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Lyon, France ]]></publisher-loc>
<publisher-name><![CDATA[International Agency for Research on Cancer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cardoso]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Senkus]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Papadopoulos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)]]></article-title>
<source><![CDATA[Annals of Oncology]]></source>
<year>2018</year>
<volume>29</volume>
<page-range>1634-57</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaufman]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Kohlhapp]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Zloza]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic viruses: a new class of immunotherapy drugs]]></article-title>
<source><![CDATA[Nat Rev Drug Discov]]></source>
<year>2015</year>
<volume>14</volume>
<page-range>642-62</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bommareddy]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hossain]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kaufman]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma]]></article-title>
<source><![CDATA[Am J Clin Dermatol]]></source>
<year>2017</year>
<volume>18</volume>
<page-range>1-15</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jhawar]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Thandoni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bommareddy]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Hassan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic viruses-natural and genetically engineered cancer immunotherapies]]></article-title>
<source><![CDATA[Front Oncol]]></source>
<year>2017</year>
<volume>7</volume>
<page-range>202</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hennessy]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Bommareddy]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Boland]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kaufman]]></surname>
<given-names><![CDATA[HL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic Immunotherapy]]></article-title>
<source><![CDATA[Surg Oncol Clin N Am]]></source>
<year>2019</year>
<volume>28</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>419-30</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cody]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hurst]]></surname>
<given-names><![CDATA[DR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Promising oncolytic agents for metastatic breast cancer treatment]]></article-title>
<source><![CDATA[Oncolytic Virotherapy]]></source>
<year>2015</year>
<volume>4</volume>
<page-range>63-73</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suryawanshi]]></surname>
<given-names><![CDATA[YR]]></given-names>
</name>
<name>
<surname><![CDATA[Zhan]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Essani]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic viruses: emerging options for the treatment of breast cancer]]></article-title>
<source><![CDATA[Med Oncol]]></source>
<year>2017</year>
<volume>34</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>43</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crompton]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Kirn]]></surname>
<given-names><![CDATA[DH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development]]></article-title>
<source><![CDATA[Curr Cancer Drug Targets]]></source>
<year>2007</year>
<volume>7</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>133-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibition of breast cancer cells by targeting E2F-1 gene and expressing IL15 oncolytic adenovirus]]></article-title>
<source><![CDATA[Biosci Rep]]></source>
<year>2019</year>
<volume>39</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dong]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Qu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potent antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo]]></article-title>
<source><![CDATA[Cancer Lett]]></source>
<year>2013</year>
<volume>328</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>95-103</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bazan-Peregrino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sainson]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Carlisle]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Thoma]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combining virotherapy and angiotherapy for the treatment of breast cancer]]></article-title>
<source><![CDATA[Cancer Gene Ther]]></source>
<year>2013</year>
<volume>20</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>461-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Guise]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Seth]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-&#946; receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model]]></article-title>
<source><![CDATA[Hum Gene Ther]]></source>
<year>2010</year>
<volume>21</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1623-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Krimmel]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host]]></article-title>
<source><![CDATA[Cancer Gene Ther]]></source>
<year>2012</year>
<volume>19</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>630-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Bai]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Qi]]></surname>
<given-names><![CDATA[YD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An oncolytic adenovirus expressing interleukin-24 enhances antitumor activities in combination with paclitaxel in breast cancer cells]]></article-title>
<source><![CDATA[Mol Med Rep]]></source>
<year>2013</year>
<volume>8</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1416-24</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bramante]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Koski]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Liikanen]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Vassilev]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer]]></article-title>
<source><![CDATA[Oncoimmunology]]></source>
<year>2015</year>
<volume>5</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hemminki]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Diaconu]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Cerullo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Pesonen]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus in patients with chemotherapy refractory cancer]]></article-title>
<source><![CDATA[Mol Ther]]></source>
<year>2012</year>
<volume>20</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1821-30</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Asad]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno Ayala]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Gottardo]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Zuccato]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Viral gene therapy for breast cancer: progress and challenges]]></article-title>
<source><![CDATA[Expert Opin Biol Ther]]></source>
<year>2017</year>
<volume>17</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>945-59</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alam]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bowser]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Israr]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Conway]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adeno-associated virus type 2 infection of nude mouse human breast cancer xenograft induces necrotic death and inhibits tumor growth]]></article-title>
<source><![CDATA[Cancer Biol Ther]]></source>
<year>2014</year>
<volume>15</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1013-28</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skelding]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Barry]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Shafren]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21]]></article-title>
<source><![CDATA[Breast Cancer Res Treat]]></source>
<year>2009</year>
<volume>113</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>21-30</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skelding]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Barry]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Shafren]]></surname>
<given-names><![CDATA[DR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride]]></article-title>
<source><![CDATA[Invest New Drugs]]></source>
<year>2012</year>
<volume>30</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>568-81</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mayo]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A summary of taxonomic changes recently approved by ICTV]]></article-title>
<source><![CDATA[Arch. Virol]]></source>
<year>2002</year>
<volume>147</volume>
<page-range>1655-63</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Janke]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fournier]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Schirrmacher]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy]]></article-title>
<source><![CDATA[Virus Res]]></source>
<year>2000</year>
<volume>136</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>75-80</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ghrici]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[El Zowalaty]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Omar]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ideris A. Induction of apoptosis in MCF-7 cells by the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus Malaysian strain AF2240]]></article-title>
<source><![CDATA[Oncol Rep]]></source>
<year>2013</year>
<volume>30</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1035-44</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ahmad]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Keong]]></surname>
<given-names><![CDATA[YY]]></given-names>
</name>
<name>
<surname><![CDATA[Abd Manan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibitory and apoptosis-inducing effects of Newcastle disease virus strain AF2240 on mammary carcinoma cell line]]></article-title>
<source><![CDATA[Biomed Res Int]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raihan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmad]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Yong]]></surname>
<given-names><![CDATA[YK]]></given-names>
</name>
<name>
<surname><![CDATA[Eshak]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Regression of solid breast tumors in mice by Newcastle disease virus is associated with production of apoptosis related cytokines]]></article-title>
<source><![CDATA[BMC Cancer]]></source>
<year>2019</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>315</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abd-Aziz]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Stanbridge]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Shafee]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Newcastle disease virus degrades HIF-1&#945; through proteasomal pathways independent of VHL and p53]]></article-title>
<source><![CDATA[J Gen Virol]]></source>
<year>2016</year>
<volume>97</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>3174-82</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amin]]></surname>
<given-names><![CDATA[MZ]]></given-names>
</name>
<name>
<surname><![CDATA[Ani]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Tan SW]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yeap]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of a recombinant newcastle disease virus expressing human IL12 against human breast cancer]]></article-title>
<source><![CDATA[Sci Rep]]></source>
<year>2019</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>13999</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O&#8217;Bryan]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Mathis]]></surname>
<given-names><![CDATA[JM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic virotherapy for breast cancer treatment]]></article-title>
<source><![CDATA[Current Gene Therapy]]></source>
<year>2018</year>
<volume>18</volume>
<page-range>192-205</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ebert]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Harbaran]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shinozaki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Woo]]></surname>
<given-names><![CDATA[SL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice]]></article-title>
<source><![CDATA[Cancer Gene Ther]]></source>
<year>2005</year>
<volume>12</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>350-8</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Puckett]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lyles]]></surname>
<given-names><![CDATA[DS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus]]></article-title>
<source><![CDATA[Cancer Gene Ther]]></source>
<year>2010</year>
<volume>17</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>883-92</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Le Boeuf]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gebremeskel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[McMullen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reovirus FAST protein enhances vesicular stomatitis virus oncolytic virotherapy in primary and metastatic tumor models]]></article-title>
<source><![CDATA[Mol Ther Oncolytics]]></source>
<year>2017</year>
<volume>6</volume>
<page-range>80-9</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[NT]]></given-names>
</name>
<name>
<surname><![CDATA[Roy]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Workenhe]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[van den Wollenberg]]></surname>
<given-names><![CDATA[DJM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Presurgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer]]></article-title>
<source><![CDATA[Sci Rep]]></source>
<year>2019</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1865</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Ning]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Zhuang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2014</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Coffin]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2006</year>
<volume>12</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>6737-47</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andtbacka]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Kaufman]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Collichio]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Amatruda]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2015</year>
<volume>33</volume>
<page-range>2780-8</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mazumder]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martuza]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2001</year>
<volume>61</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>3009-15</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Nemunaitis]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Herpes simplex virus 1 (HSV-1) for cancer treatment]]></article-title>
<source><![CDATA[Cancer Gene Ther]]></source>
<year>2006</year>
<volume>13</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>975-92</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Teshigahara]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Goshima]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Takao]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kohno]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10]]></article-title>
<source><![CDATA[J Surg Oncol]]></source>
<year>2004</year>
<volume>85</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kimata]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Imai]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kikumori]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Teshigahara]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2006</year>
<volume>13</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1078-84</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sahin]]></surname>
<given-names><![CDATA[TT]]></given-names>
</name>
<name>
<surname><![CDATA[Kasuya]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Nomura]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Shikano]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer]]></article-title>
<source><![CDATA[Cancer Gene Ther]]></source>
<year>2012</year>
<volume>19</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>229-37</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Varghese]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rabkin]]></surname>
<given-names><![CDATA[SD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2005</year>
<volume>65</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1532-40</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cody]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Scaturro]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cantor]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Yancey Gillespie]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preclinical evaluation of oncolytic &#948;&#947;(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases]]></article-title>
<source><![CDATA[Int J Breast Cancer]]></source>
<year>2012</year>
<volume>2012</volume>
<page-range>628697</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[LW]]></given-names>
</name>
<name>
<surname><![CDATA[Shillitoe]]></surname>
<given-names><![CDATA[EJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of a caspase inhibitor, zVADfmk, on the inhibition of breast cancer cells by herpes simplex virus type 1]]></article-title>
<source><![CDATA[Cancer Gene Ther]]></source>
<year>2011</year>
<volume>18</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>685-94</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kasuya]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sahin]]></surname>
<given-names><![CDATA[TT]]></given-names>
</name>
<name>
<surname><![CDATA[Yamamura]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2015</year>
<volume>136</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1718-30</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Conner]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Braidwood]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy]]></article-title>
<source><![CDATA[Cancer Gene Ther]]></source>
<year>2012</year>
<volume>19</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>499-507</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cuddington]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
<name>
<surname><![CDATA[Dyer]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Workenhe]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Mossman]]></surname>
<given-names><![CDATA[KL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic bovine herpesvirus type 1 infects and kills breast tumor cells and breast cancer-initiating cells irrespective of tumor subtype]]></article-title>
<source><![CDATA[Cancer Gene Ther]]></source>
<year>2013</year>
<volume>20</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>282-9</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brun]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[McManus]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lefebvre]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of genetically modified Maraba virus as an oncolytic rhabdovirus]]></article-title>
<source><![CDATA[Mol Ther]]></source>
<year>2010</year>
<volume>18</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1440-9</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bourgeois-Daigneault]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[St-Germain]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Roy]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Pelin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment]]></article-title>
<source><![CDATA[Breast Cancer Res]]></source>
<year>2016</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>83</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bourgeois-Daigneault]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Roy]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Aitken]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[El Sayes]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy]]></article-title>
<source><![CDATA[Sci Transl Med]]></source>
<year>2018</year>
<volume>10</volume>
<numero>422</numero>
<issue>422</issue>
</nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choi AH]]></surname>
<given-names><![CDATA[O&amp;apos]]></given-names>
</name>
<name>
<surname><![CDATA[Leary MP]]></surname>
<given-names><![CDATA[Kim SI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Endogenous Akt activity promotes virus entry and predicts efficacy of novel chimeric Orthopoxvirus in Triple-Negative Breast Cancer]]></article-title>
<source><![CDATA[Mol Ther Oncolytics]]></source>
<year>2018</year>
<volume>9</volume>
<page-range>22-9</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choi AH]]></surname>
<given-names><![CDATA[O&amp;apos]]></given-names>
</name>
<name>
<surname><![CDATA[Leary MP]]></surname>
<given-names><![CDATA[Lu J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Novel chimeric parapoxvirus CF189 as an oncolytic immunotherapy in triple-negative breast cancer]]></article-title>
<source><![CDATA[Surgery]]></source>
<year>2018</year>
<volume>163</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>336-42</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maxwell]]></surname>
<given-names><![CDATA[IH]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Scherrer]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Spitzer]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expansion of tropism of a feline parvovirus to target a human tumor cell line by display of an alpha(v) integrin binding peptide on the capsid]]></article-title>
<source><![CDATA[Gene Ther]]></source>
<year>2001</year>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>324-31</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muharram]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Le Rhun]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Loison]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Wizla]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Parvovirus H-1 induces cytopathic effects in breast carcinoma-derived cultures]]></article-title>
<source><![CDATA[Breast Cancer Res Treat]]></source>
<year>2010</year>
<volume>121</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>23-33</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ansardi]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Porter]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Gillespie]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[RNA replicons derived from poliovirus are directly oncolytic for human tumor cells of diverse origins]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2001</year>
<volume>61</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>8470-9</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ochiai]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Archer]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Okamura]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2004</year>
<volume>10</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>4831-8</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Holl]]></surname>
<given-names><![CDATA[EK]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Boczkowski]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[McNamara]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models]]></article-title>
<source><![CDATA[Oncotarget]]></source>
<year>2016</year>
<volume>7</volume>
<numero>48</numero>
<issue>48</issue>
<page-range>79828-41</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clements]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Helson]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gujar]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[PW.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reovirus in cancer therapy: an evidence-based review]]></article-title>
<source><![CDATA[Oncolytic Virother]]></source>
<year>2014</year>
<volume>3</volume>
<page-range>69-82</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marcato]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Dean]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Giacomantonio]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[PW.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic Reovirus effectively targets breast cancer stem cells]]></article-title>
<source><![CDATA[Mol Ther]]></source>
<year>2009</year>
<volume>17</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>972-9</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thirukkumaran]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[ZQ]]></given-names>
</name>
<name>
<surname><![CDATA[Thirukkumaran]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Luider]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PUMA and NF-kB Are Cell Signaling Predictors of Reovirus Oncolysis of Breast Cancer]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2017</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mostafa]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Meyers]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Thirukkumaran]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic Reovirus and immune checkpoint inhibition as a novel immunotherapeutic strategy for breast cancer]]></article-title>
<source><![CDATA[Cancers (Basel)]]></source>
<year>2018</year>
<volume>10</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez Stewart]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Berry]]></surname>
<given-names><![CDATA[JTL]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Yoon]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enhanced killing of triple-negative breast cancer cells by reassortant Reovirus and topoisomerase inhibitors]]></article-title>
<source><![CDATA[J Virol]]></source>
<year>2019</year>
<page-range>JVI.01411-9</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sugiyama]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yoneda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kuraishi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hattori]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment]]></article-title>
<source><![CDATA[Gene Ther]]></source>
<year>2013</year>
<volume>20</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>338-47</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Griffin]]></surname>
<given-names><![CDATA[DE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Measles virus]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[David]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Knipe]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Peter]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Howley]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Griffin]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Lamb]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Malcolm]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bernard Roizman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Stephen]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Straus]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Fields Virology]]></source>
<year>2006</year>
<page-range>1401-586</page-range><publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[Lippincott Williams &amp; Wilkins]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Msaouel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Iankov]]></surname>
<given-names><![CDATA[ID]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Engineered measles virus as a novel oncolytic therapy against prostate cancer]]></article-title>
<source><![CDATA[Prostate]]></source>
<year>2009</year>
<volume>69</volume>
<page-range>82-91</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Paraskevakou]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Iankov]]></surname>
<given-names><![CDATA[ID]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic measles virus strains in the treatment of gliomas]]></article-title>
<source><![CDATA[Expert Opin Biol Ther]]></source>
<year>2008</year>
<volume>8</volume>
<page-range>213-20</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>67</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McDonald]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Erlichman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ingle]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Rosales]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer]]></article-title>
<source><![CDATA[Breast Cancer Res Treat]]></source>
<year>2006</year>
<page-range>177-84</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blechacz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Splinter]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Greiner]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Myers]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma]]></article-title>
<source><![CDATA[Hepatology]]></source>
<year>2006</year>
<volume>44</volume>
<page-range>1465-77</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iankov]]></surname>
<given-names><![CDATA[ID]]></given-names>
</name>
<name>
<surname><![CDATA[Msaouel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Federspiel]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model]]></article-title>
<source><![CDATA[Breast Cancer Res Treat]]></source>
<year>2010</year>
<volume>122</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>745-54</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Erlichman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[McDonald]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ingle]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heat shock protein inhibitors increase the efficacy of measles virotherapy]]></article-title>
<source><![CDATA[Gene Ther]]></source>
<year>2008</year>
<volume>15</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1024-34</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>71</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Opyrchal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Msaouel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Iankov]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibition of Rho-associated coiled-coil-forming kinase increases efficacy of measles virotherapy]]></article-title>
<source><![CDATA[Cancer Gene Ther]]></source>
<year>2013</year>
<volume>20</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>630-7</page-range></nlm-citation>
</ref>
<ref id="B72">
<label>72</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iankov ID]]></surname>
<given-names><![CDATA[D&amp;apos]]></given-names>
</name>
<name>
<surname><![CDATA[Assoro AB]]></surname>
<given-names><![CDATA[Ingle JN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy]]></article-title>
<source><![CDATA[Cancer Gene Ther]]></source>
<year>2015</year>
<volume>22</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>438-44</page-range></nlm-citation>
</ref>
<ref id="B73">
<label>73</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jing]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Bejarano]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Zaias]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Merchan]]></surname>
<given-names><![CDATA[JR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer]]></article-title>
<source><![CDATA[Breast Cancer Res Treat]]></source>
<year>2015</year>
<volume>149</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>99-108</page-range></nlm-citation>
</ref>
<ref id="B74">
<label>74</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jing]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Chavez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Ban]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Acquavella]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer]]></article-title>
<source><![CDATA[Mol Cancer Res]]></source>
<year>2017</year>
<volume>15</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1410-20</page-range></nlm-citation>
</ref>
<ref id="B75">
<label>75</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[LY]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[XX]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zang]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inactivated Sendai virus strain Tianjin induces apoptosis in breast cancer MCF-7 cells by promoting caspase activation and Fas/FasL expression]]></article-title>
<source><![CDATA[Cancer Biother Radiopharm]]></source>
<year>2015</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33-40</page-range></nlm-citation>
</ref>
<ref id="B76">
<label>76</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[YA]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2007</year>
<volume>67</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>10038-46</page-range></nlm-citation>
</ref>
<ref id="B77">
<label>77</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seubert]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Stritzker]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hess]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Donat]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Sturm]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[von Hof]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Krewer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Tietze]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Gentschev]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Szalay]]></surname>
<given-names><![CDATA[AA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a &#946;-galactosidase-activatable prodrug seco-analog of duocarmycin SA]]></article-title>
<source><![CDATA[Cancer Gene Ther]]></source>
<year>2011</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>42-52</page-range></nlm-citation>
</ref>
<ref id="B78">
<label>78</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hofmann]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Grummt]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Szalay]]></surname>
<given-names><![CDATA[AA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vaccinia virus GLV-1h237 carrying a Walker A motif mutation of mouse Cdc6 protein enhances human breast tumor therapy in mouse xenografts]]></article-title>
<source><![CDATA[Int J Oncol]]></source>
<year>2011</year>
<volume>38</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B79">
<label>79</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haddad]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2012</year>
<volume>19</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>S665-74</page-range></nlm-citation>
</ref>
<ref id="B80">
<label>80</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gil]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Seshadri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Komorowski]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Abrams]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases]]></article-title>
<source><![CDATA[Proc Natl Acad Sci USA]]></source>
<year>2013</year>
<volume>110</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>E1291-300</page-range></nlm-citation>
</ref>
<ref id="B81">
<label>81</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gholami]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Belin]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lou]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vaccinia virus GLV-1h153 is a novel agent for detection and effective local control of positive surgical margins for breast cancer]]></article-title>
<source><![CDATA[Breast Cancer Res]]></source>
<year>2013</year>
<volume>15</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>R26</page-range></nlm-citation>
</ref>
<ref id="B82">
<label>82</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gholami]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Marano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer]]></article-title>
<source><![CDATA[Breast Cancer Res Treat]]></source>
<year>2014</year>
<volume>148</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>489-99</page-range></nlm-citation>
</ref>
<ref id="B83">
<label>83</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eissa]]></surname>
<given-names><![CDATA[IR]]></given-names>
</name>
<name>
<surname><![CDATA[Bustos-Villalobos]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ichinose]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Matsumura]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Naoe]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Miyajima]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Morimoto]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mukoyama]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Zhiwen]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hasegawa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sumigama]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Aleksic]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kodera]]></surname>
<given-names><![CDATA[Kasuya H. T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[he Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast]]></article-title>
<source><![CDATA[Cancers]]></source>
<year>2018</year>
<volume>10</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>356</page-range></nlm-citation>
</ref>
<ref id="B84">
<label>84</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heise]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hermiston]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Brooks]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy]]></article-title>
<source><![CDATA[Nat Med]]></source>
<year>2000</year>
<volume>6</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1134-9</page-range></nlm-citation>
</ref>
<ref id="B85">
<label>85</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
<name>
<surname><![CDATA[Seong]]></surname>
<given-names><![CDATA[YR]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor]]></article-title>
<source><![CDATA[Mol Ther]]></source>
<year>2004</year>
<volume>10</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>938-49</page-range></nlm-citation>
</ref>
<ref id="B86">
<label>86</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[CX]]></given-names>
</name>
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The human SCGB2A2 (mammaglobin-1) promoter/enhancer in a helper-dependent adenovirus vector directs high levels of transgene expression in mammary carcinoma cells but not in normal nonmammary cells]]></article-title>
<source><![CDATA[Mol Ther]]></source>
<year>2004</year>
<volume>10</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>758-67</page-range></nlm-citation>
</ref>
<ref id="B87">
<label>87</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Thorne]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hannock]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2005</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>351-60</page-range></nlm-citation>
</ref>
<ref id="B88">
<label>88</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[ZG]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Ramachandra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Seth]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An oncolytic adenovirus expressing soluble transforming growth factor-beta type II receptor for targeting breast cancer: in vitro evaluation]]></article-title>
<source><![CDATA[Mol Cancer Ther]]></source>
<year>2006</year>
<volume>5</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>367-73</page-range></nlm-citation>
</ref>
<ref id="B89">
<label>89</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stoff-Khalili]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Stoff]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Michael Mathis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2007</year>
<volume>120</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>935-41</page-range></nlm-citation>
</ref>
<ref id="B90">
<label>90</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hakkarainen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Särkioja]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lehenkari]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Miettinen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors]]></article-title>
<source><![CDATA[Hum Gene Ther]]></source>
<year>2007</year>
<volume>18</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>627-41</page-range></nlm-citation>
</ref>
<ref id="B91">
<label>91</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ranki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kanerva]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ristimäki]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hakkarainen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer]]></article-title>
<source><![CDATA[Gene Ther]]></source>
<year>2007</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>58-67</page-range></nlm-citation>
</ref>
<ref id="B92">
<label>92</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ranki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Särkioja]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hakkarainen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[von Smitten]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2007</year>
<volume>121</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>165-74</page-range></nlm-citation>
</ref>
<ref id="B93">
<label>93</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eriksson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Guse]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Bauerschmitz]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Virkkunen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells]]></article-title>
<source><![CDATA[Mol Ther]]></source>
<year>2007</year>
<volume>15</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2088-93</page-range></nlm-citation>
</ref>
<ref id="B94">
<label>94</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bauerschmitz]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ranki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kangasniemi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ribacka]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tissue-specific promoters active in CD44+CD24-/low breast cancer cells]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2008</year>
<volume>68</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>5533-9</page-range></nlm-citation>
</ref>
<ref id="B95">
<label>95</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gomes]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Phadke]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Butcher]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2009</year>
<volume>15</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1317-25</page-range></nlm-citation>
</ref>
<ref id="B96">
<label>96</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yoo]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Ryu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Yaguchi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor suppression by apoptotic and anti-angiogenic effects of mortalin-targeting adeno-oncolytic virus]]></article-title>
<source><![CDATA[J Gene Med]]></source>
<year>2010</year>
<volume>12</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>586-95</page-range></nlm-citation>
</ref>
<ref id="B97">
<label>97</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Dai]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Deng]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HSF1 overexpression enhances oncolytic effect of replicative adenovirus]]></article-title>
<source><![CDATA[J Transl Med]]></source>
<year>2010</year>
<volume>8</volume>
<page-range>44</page-range></nlm-citation>
</ref>
<ref id="B98">
<label>98</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Robbins]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Pister]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zafar]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy]]></article-title>
<source><![CDATA[Cancer Gene Ther]]></source>
<year>2010</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>235-43</page-range></nlm-citation>
</ref>
<ref id="B99">
<label>99</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dembinski]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Spaeth]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Fueyo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez-Manzano]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells]]></article-title>
<source><![CDATA[Cancer Gene Ther]]></source>
<year>2010</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>289-97</page-range></nlm-citation>
</ref>
<ref id="B100">
<label>100</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Krimmel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model]]></article-title>
<source><![CDATA[Hum Gene Ther]]></source>
<year>2011</year>
<volume>22</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1137-42</page-range></nlm-citation>
</ref>
<ref id="B101">
<label>101</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo]]></article-title>
<source><![CDATA[J Exp Clin Cancer Res]]></source>
<year>2012</year>
<volume>31</volume>
<page-range>51</page-range></nlm-citation>
</ref>
<ref id="B102">
<label>102</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer]]></article-title>
<source><![CDATA[Cancer Biol Ther]]></source>
<year>2013</year>
<volume>14</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1016-23</page-range></nlm-citation>
</ref>
<ref id="B103">
<label>103</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Neill]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases]]></article-title>
<source><![CDATA[Hum Gene Ther]]></source>
<year>2015</year>
<volume>26</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>813-25</page-range></nlm-citation>
</ref>
<ref id="B104">
<label>104</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Synergistic antitumor effect of adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase and nucleoside analogs for human breast carcinoma in vitro and in vivo]]></article-title>
<source><![CDATA[Drug Des Devel Ther]]></source>
<year>2015</year>
<page-range>3301-12</page-range></nlm-citation>
</ref>
<ref id="B105">
<label>105</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liikanen]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Tähtinen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Guse]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gutmann]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer]]></article-title>
<source><![CDATA[Mol Cancer Ther]]></source>
<year>2016</year>
<volume>15</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2259-69</page-range></nlm-citation>
</ref>
<ref id="B106">
<label>106</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shayestehpour]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Moghim]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Salimi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Jalilvand]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeting human breast cancer cells by an oncolytic adenovirus using microRNA-targeting strategy]]></article-title>
<source><![CDATA[Virus Res]]></source>
<year>2017</year>
<volume>240</volume>
<page-range>207-14</page-range></nlm-citation>
</ref>
<ref id="B107">
<label>107</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garza-Morales]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez-Ramos]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chiba]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Montes de Oca-Luna]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Temozolomide Enhances Triple-Negative Breast Cancer Virotherapy In Vitro]]></article-title>
<source><![CDATA[Cancers (Basel)]]></source>
<year>2018</year>
<volume>10</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B108">
<label>108</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[YQ]]></given-names>
</name>
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[XZ]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[SZ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recombinant adenoviruses expressing apoptin suppress the growth of MCF-7 breast cancer cells and affect cell autophagy]]></article-title>
<source><![CDATA[Oncol Rep]]></source>
<year>2019</year>
<volume>41</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>2818-32</page-range></nlm-citation>
</ref>
<ref id="B109">
<label>109</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernandez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Porosnicu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Markovic]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Barber]]></surname>
<given-names><![CDATA[GN.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease]]></article-title>
<source><![CDATA[J Virol]]></source>
<year>2002</year>
<volume>76</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>895-904</page-range></nlm-citation>
</ref>
<ref id="B110">
<label>110</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bergman]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Whitaker-Dowling]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Griffin]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vesicular stomatitis virus expressing a chimeric Sindbis glycoprotein containing an Fc antibody binding domain targets to Her2/neu overexpressing breast cancer cells]]></article-title>
<source><![CDATA[Virology]]></source>
<year>2003</year>
<volume>316</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>337-47</page-range></nlm-citation>
</ref>
<ref id="B111">
<label>111</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bergman]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Griffin]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Whitaker-Dowling]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2007</year>
<volume>121</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>425-30</page-range></nlm-citation>
</ref>
<ref id="B112">
<label>112</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jha]]></surname>
<given-names><![CDATA[BK]]></given-names>
</name>
<name>
<surname><![CDATA[Dong]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Polyakova]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Supression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy]]></article-title>
<source><![CDATA[Mol Ther]]></source>
<year>2013</year>
<volume>21</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1749-57</page-range></nlm-citation>
</ref>
<ref id="B113">
<label>113</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[YP]]></given-names>
</name>
<name>
<surname><![CDATA[Suksanpaisan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Steele]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Russell]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy]]></article-title>
<source><![CDATA[Sci Rep]]></source>
<year>2013</year>
<volume>3</volume>
<page-range>2375</page-range></nlm-citation>
</ref>
<ref id="B114">
<label>114</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garijo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Alonso]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rivas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Diallo]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Experimental evolution of an oncolytic vesicular stomatitis virus with increased selectivity for p53-deficient cells]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2014</year>
<volume>9</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B115">
<label>115</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Fraser]]></surname>
<given-names><![CDATA[NW.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer]]></article-title>
<source><![CDATA[Mol Ther]]></source>
<year>2003</year>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>543-51</page-range></nlm-citation>
</ref>
<ref id="B116">
<label>116</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Martuza]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Rabkin]]></surname>
<given-names><![CDATA[SD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain]]></article-title>
<source><![CDATA[Gene Ther]]></source>
<year>2005</year>
<volume>12</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>647-54</page-range></nlm-citation>
</ref>
<ref id="B117">
<label>117</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Rabkin]]></surname>
<given-names><![CDATA[SD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic herpes simplex virus vectors for the treatment of human breast cancer]]></article-title>
<source><![CDATA[Chin Med J (Engl)]]></source>
<year>2005</year>
<volume>118</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>307-12</page-range></nlm-citation>
</ref>
<ref id="B118">
<label>118</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Tao]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cai]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Prigge]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus]]></article-title>
<source><![CDATA[Mol Ther]]></source>
<year>2006</year>
<volume>13</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>882-90</page-range></nlm-citation>
</ref>
<ref id="B119">
<label>119</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greco]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Joiner]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Doleh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Powell]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypoxia- and radiation-activated Cre/loxP &amp;apos;molecular switch&amp;apos; vectors for gene therapy of cancer]]></article-title>
<source><![CDATA[Gene Ther]]></source>
<year>2006</year>
<volume>13</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>206-15</page-range></nlm-citation>
</ref>
<ref id="B120">
<label>120</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Menotti]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cerretani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Campadelli-Fiume]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumour receptor, independently of the gD receptors]]></article-title>
<source><![CDATA[J Virol]]></source>
<year>2006</year>
<volume>80</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>5531-9</page-range></nlm-citation>
</ref>
<ref id="B121">
<label>121</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stiles]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Adusumilli]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Stanziale]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Eisenberg]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estrogen enhances the efficacy of an oncolytic HSV-1 mutant in the treatment of estrogen receptor-positive breast cancer]]></article-title>
<source><![CDATA[Int J Oncol]]></source>
<year>2006</year>
<volume>28</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1429-39</page-range></nlm-citation>
</ref>
<ref id="B122">
<label>122</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Dutuor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model]]></article-title>
<source><![CDATA[J Gene Med]]></source>
<year>2007</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>161-9</page-range></nlm-citation>
</ref>
<ref id="B123">
<label>123</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Israyelyan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chouljenko]]></surname>
<given-names><![CDATA[VN]]></given-names>
</name>
<name>
<surname><![CDATA[Baghian]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[David]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice]]></article-title>
<source><![CDATA[Virol J]]></source>
<year>2008</year>
<volume>5</volume>
<numero>68</numero>
<issue>68</issue>
</nlm-citation>
</ref>
<ref id="B124">
<label>124</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Israyelyan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Shannon]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Baghian]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kearney]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thalidomide suppressed the growth of 4T1 cells into solid tumors in Balb/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn]]></article-title>
<source><![CDATA[Cancer Chemother Pharmacol]]></source>
<year>2009</year>
<volume>64</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1201-10</page-range></nlm-citation>
</ref>
<ref id="B125">
<label>125</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fasullo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Burch]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Britton]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypoxia enhances the replication of oncolytic herpes simplex virus in p53- breast cancer cells]]></article-title>
<source><![CDATA[Cell Cycle]]></source>
<year>2009</year>
<volume>8</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>2194-7</page-range></nlm-citation>
</ref>
<ref id="B126">
<label>126</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Sehgal]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Kousoulas]]></surname>
<given-names><![CDATA[KG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice]]></article-title>
<source><![CDATA[J Virol]]></source>
<year>2011</year>
<volume>85</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>7363-71</page-range></nlm-citation>
</ref>
<ref id="B127">
<label>127</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zeng]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of breast cancer stem cells with oncolytic herpes simplex virus]]></article-title>
<source><![CDATA[Cancer Gene Ther]]></source>
<year>2012</year>
<volume>19</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>707-14</page-range></nlm-citation>
</ref>
<ref id="B128">
<label>128</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Zeng]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rabkin]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic herpes simplex virus treatment of metastatic breast cancer]]></article-title>
<source><![CDATA[Int J Oncol]]></source>
<year>2012</year>
<volume>40</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>757-63</page-range></nlm-citation>
</ref>
<ref id="B129">
<label>129</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zeng]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The oncolytic herpes simplex virus vector G47&#8710; effectively targets breast cancer stem cells]]></article-title>
<source><![CDATA[Oncol Rep]]></source>
<year>2013</year>
<volume>29</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1108-14</page-range></nlm-citation>
</ref>
<ref id="B130">
<label>130</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zeng]]></surname>
<given-names><![CDATA[WG]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lei]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An oncolytic herpes simplex virus vector, G47&#916;, synergizes with paclitaxel in the treatment of breast cancer]]></article-title>
<source><![CDATA[Oncol Rep]]></source>
<year>2013</year>
<volume>29</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2355-61</page-range></nlm-citation>
</ref>
<ref id="B131">
<label>131</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cody]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Markert]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Hurst]]></surname>
<given-names><![CDATA[DR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2014</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B132">
<label>132</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gholami]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Marano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer]]></article-title>
<source><![CDATA[Breast Cancer Res Treat]]></source>
<year>2014</year>
<volume>148</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>489-99</page-range></nlm-citation>
</ref>
<ref id="B133">
<label>133</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meisen]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Dubin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sizemore]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Mathsyaraja]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Changes in BAI1 and nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targeted therapies]]></article-title>
<source><![CDATA[Mol Cancer Ther]]></source>
<year>2015</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>307-14</page-range></nlm-citation>
</ref>
<ref id="B134">
<label>134</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuruppu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Tanabe]]></surname>
<given-names><![CDATA[KK.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HSV-1 as a novel therapy for breast cancer meningeal metastases]]></article-title>
<source><![CDATA[Cancer Gene Ther]]></source>
<year>2015</year>
<volume>22</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>506-8</page-range></nlm-citation>
</ref>
<ref id="B135">
<label>135</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leoni]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Gatta]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Palladini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nicoletti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases]]></article-title>
<source><![CDATA[Oncotarget]]></source>
<year>2015</year>
<volume>6</volume>
<numero>33</numero>
<issue>33</issue>
<page-range>34774-87</page-range></nlm-citation>
</ref>
<ref id="B136">
<label>136</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cuddington]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
<name>
<surname><![CDATA[Verschoor]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ashkar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mossman]]></surname>
<given-names><![CDATA[KL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enhanced efficacy with azacytidine and oncolytic BHV-1 in a tolerized cotton rat model of breast adenocarcinoma]]></article-title>
<source><![CDATA[Mol Ther Oncolytics]]></source>
<year>2015</year>
<volume>2</volume>
<page-range>15004</page-range></nlm-citation>
</ref>
<ref id="B137">
<label>137</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Workenhe]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Ketela]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Moffat]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cuddington]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells]]></article-title>
<source><![CDATA[Oncogene]]></source>
<year>2016</year>
<volume>35</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>2465-74</page-range></nlm-citation>
</ref>
<ref id="B138">
<label>138</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases]]></article-title>
<source><![CDATA[Oncotarget]]></source>
<year>2016</year>
<volume>7</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>27764-77</page-range></nlm-citation>
</ref>
<ref id="B139">
<label>139</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pourchet]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fuhrmann]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Pilones]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Demaria]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CD8(+) T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy]]></article-title>
<source><![CDATA[EBioMedicine]]></source>
<year>2016</year>
<volume>5</volume>
<page-range>59-67</page-range></nlm-citation>
</ref>
<ref id="B140">
<label>140</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ruan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A novel oncolytic herpes simplex virus armed with the carboxyl-terminus of murine MyD116 has enhanced anti-tumour efficacy against human breast cancer cells]]></article-title>
<source><![CDATA[Oncol Lett]]></source>
<year>2018</year>
<volume>15</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>7046-52</page-range></nlm-citation>
</ref>
<ref id="B141">
<label>141</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weiland]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lampe]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Essmann]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Venturelli]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enhanced killing of therapy-induced senescent tumor cells by oncolytic measles vaccine viruses]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2014</year>
<volume>134</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>235-43</page-range></nlm-citation>
</ref>
<ref id="B142">
<label>142</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tai]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chemovirotherapeutic Treatment Using Camptothecin Enhances Oncolytic Measles Virus-Mediated Killing of Breast Cancer Cells]]></article-title>
<source><![CDATA[Sci Rep]]></source>
<year>2019</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>6767</page-range></nlm-citation>
</ref>
<ref id="B143">
<label>143</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lal]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rajala]]></surname>
<given-names><![CDATA[MS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combination of oncolytic measles virus armed With BNiP3, a pro-apoptotic gene and paclitaxel induces breast cancer cell death]]></article-title>
<source><![CDATA[Front Oncol]]></source>
<year>2019</year>
<volume>8</volume>
<page-range>676</page-range></nlm-citation>
</ref>
<ref id="B144">
<label>144</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
<name>
<surname><![CDATA[Minev]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
<name>
<surname><![CDATA[Szalay]]></surname>
<given-names><![CDATA[AA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells]]></article-title>
<source><![CDATA[J Transl Med]]></source>
<year>2012</year>
<volume>10</volume>
<page-range>167</page-range></nlm-citation>
</ref>
<ref id="B145">
<label>145</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gholami]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Lou]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[De Brot]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vaccinia virus GLV-1h153 is effective in treating and preventing metastatic triple-negative breast cancer]]></article-title>
<source><![CDATA[Ann Surg]]></source>
<year>2012</year>
<volume>256</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>437-45</page-range></nlm-citation>
</ref>
<ref id="B146">
<label>146</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kochneva]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sivolobova]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tkacheva]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Grazhdantseva]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy]]></article-title>
<source><![CDATA[Oncotarget]]></source>
<year>2016</year>
<volume>7</volume>
<numero>45</numero>
<issue>45</issue>
<page-range>74171-88</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
